UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million  
6/9/2011 10:24:03 AM

DARMSTADT, Germany--(BUSINESS WIRE)--Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRICa has been completed. CENTRIC was designed to assess the efficacy and safety of the investigational integrin inhibitor cilengitide in combination with standard treatment in a biomarker-defined subgroup of newly diagnosed patients with glioblastoma (GBM). More than 500 patients have been successfully recruited into this global trial. The primary endpoint of the study is overall survival.